vs

Side-by-side financial comparison of MCGRATH RENTCORP (MGRC) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $198.5M, roughly 1.0× MCGRATH RENTCORP). MCGRATH RENTCORP runs the higher net margin — 13.6% vs -62.0%, a 75.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -12.6%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -3.4%).

McGrath RentCorp is a leading North American B2B rental provider. It offers relocatable modular office and classroom buildings, portable storage units, and electronic test and measurement equipment, serving construction, education, industrial and technology sector clients across the U.S. and parts of Canada.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

MGRC vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.0× larger
RARE
$207.3M
$198.5M
MGRC
Growing faster (revenue YoY)
RARE
RARE
+38.5% gap
RARE
25.9%
-12.6%
MGRC
Higher net margin
MGRC
MGRC
75.6% more per $
MGRC
13.6%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-3.4%
MGRC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MGRC
MGRC
RARE
RARE
Revenue
$198.5M
$207.3M
Net Profit
$27.0M
$-128.6M
Gross Margin
48.8%
Operating Margin
21.9%
-54.7%
Net Margin
13.6%
-62.0%
Revenue YoY
-12.6%
25.9%
Net Profit YoY
-4.2%
3.5%
EPS (diluted)
$1.10
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MGRC
MGRC
RARE
RARE
Q1 26
$198.5M
Q4 25
$256.8M
$207.3M
Q3 25
$256.4M
$159.9M
Q2 25
$235.6M
$166.5M
Q1 25
$195.4M
$139.3M
Q4 24
$243.7M
$164.6M
Q3 24
$266.8M
$139.5M
Q2 24
$212.6M
$147.0M
Net Profit
MGRC
MGRC
RARE
RARE
Q1 26
$27.0M
Q4 25
$49.8M
$-128.6M
Q3 25
$42.3M
$-180.4M
Q2 25
$36.0M
$-115.0M
Q1 25
$28.2M
$-151.1M
Q4 24
$38.9M
$-133.2M
Q3 24
$149.3M
$-133.5M
Q2 24
$20.6M
$-131.6M
Gross Margin
MGRC
MGRC
RARE
RARE
Q1 26
48.8%
Q4 25
50.1%
Q3 25
46.5%
Q2 25
47.0%
Q1 25
49.3%
Q4 24
47.1%
Q3 24
46.5%
Q2 24
48.6%
Operating Margin
MGRC
MGRC
RARE
RARE
Q1 26
21.9%
Q4 25
28.9%
-54.7%
Q3 25
26.0%
-106.9%
Q2 25
24.3%
-64.8%
Q1 25
23.3%
-102.6%
Q4 24
25.9%
-74.3%
Q3 24
28.0%
-94.6%
Q2 24
25.6%
-79.1%
Net Margin
MGRC
MGRC
RARE
RARE
Q1 26
13.6%
Q4 25
19.4%
-62.0%
Q3 25
16.5%
-112.8%
Q2 25
15.3%
-69.0%
Q1 25
14.4%
-108.5%
Q4 24
16.0%
-80.9%
Q3 24
56.0%
-95.7%
Q2 24
9.7%
-89.5%
EPS (diluted)
MGRC
MGRC
RARE
RARE
Q1 26
$1.10
Q4 25
$2.02
$-1.28
Q3 25
$1.72
$-1.81
Q2 25
$1.46
$-1.17
Q1 25
$1.15
$-1.57
Q4 24
$1.58
$-1.34
Q3 24
$6.08
$-1.40
Q2 24
$0.84
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MGRC
MGRC
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-80.0M
Total Assets
$2.4B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MGRC
MGRC
RARE
RARE
Q1 26
Q4 25
$295.0K
$421.0M
Q3 25
$7.3M
$202.5M
Q2 25
$1.5M
$176.3M
Q1 25
$3.4M
$127.1M
Q4 24
$807.0K
$174.0M
Q3 24
$4.1M
$150.6M
Q2 24
$9.4M
$480.7M
Stockholders' Equity
MGRC
MGRC
RARE
RARE
Q1 26
Q4 25
$1.2B
$-80.0M
Q3 25
$1.2B
$9.2M
Q2 25
$1.2B
$151.3M
Q1 25
$1.1B
$144.2M
Q4 24
$1.1B
$255.0M
Q3 24
$1.1B
$346.8M
Q2 24
$954.2M
$432.4M
Total Assets
MGRC
MGRC
RARE
RARE
Q1 26
$2.4B
Q4 25
$2.4B
$1.5B
Q3 25
$2.4B
$1.2B
Q2 25
$2.3B
$1.3B
Q1 25
$2.2B
$1.3B
Q4 24
$2.3B
$1.5B
Q3 24
$2.3B
$1.5B
Q2 24
$2.3B
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MGRC
MGRC
RARE
RARE
Operating Cash FlowLast quarter
$42.4M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
1.57×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MGRC
MGRC
RARE
RARE
Q1 26
$42.4M
Q4 25
$80.9M
$-99.8M
Q3 25
$65.1M
$-91.4M
Q2 25
$55.8M
$-108.3M
Q1 25
$53.9M
$-166.5M
Q4 24
$36.8M
$-79.3M
Q3 24
$199.0M
$-67.0M
Q2 24
$79.2M
$-77.0M
Free Cash Flow
MGRC
MGRC
RARE
RARE
Q1 26
Q4 25
$69.8M
$-100.8M
Q3 25
$53.5M
$-92.7M
Q2 25
$38.2M
$-110.7M
Q1 25
$49.9M
$-167.8M
Q4 24
$32.6M
$-79.5M
Q3 24
$193.0M
$-68.6M
Q2 24
$74.4M
$-79.0M
FCF Margin
MGRC
MGRC
RARE
RARE
Q1 26
Q4 25
27.2%
-48.6%
Q3 25
20.8%
-58.0%
Q2 25
16.2%
-66.5%
Q1 25
25.5%
-120.5%
Q4 24
13.4%
-48.3%
Q3 24
72.4%
-49.2%
Q2 24
35.0%
-53.7%
Capex Intensity
MGRC
MGRC
RARE
RARE
Q1 26
Q4 25
4.3%
0.5%
Q3 25
4.5%
0.8%
Q2 25
7.5%
1.5%
Q1 25
2.0%
1.0%
Q4 24
1.7%
0.1%
Q3 24
2.2%
1.2%
Q2 24
2.3%
1.4%
Cash Conversion
MGRC
MGRC
RARE
RARE
Q1 26
1.57×
Q4 25
1.62×
Q3 25
1.54×
Q2 25
1.55×
Q1 25
1.91×
Q4 24
0.94×
Q3 24
1.33×
Q2 24
3.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MGRC
MGRC

Rental$126.7M64%
Rental related services$35.6M18%
Sales$34.0M17%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons